GB2020291A - Hydrocortisone 17-butyrate 21-propionate - Google Patents

Hydrocortisone 17-butyrate 21-propionate

Info

Publication number
GB2020291A
GB2020291A GB7908189A GB7908189A GB2020291A GB 2020291 A GB2020291 A GB 2020291A GB 7908189 A GB7908189 A GB 7908189A GB 7908189 A GB7908189 A GB 7908189A GB 2020291 A GB2020291 A GB 2020291A
Authority
GB
United Kingdom
Prior art keywords
hydrocortisone
butyrate
propionate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB7908189A
Other versions
GB2020291B (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of GB2020291A publication Critical patent/GB2020291A/en
Application granted granted Critical
Publication of GB2020291B publication Critical patent/GB2020291B/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
GB7908189A 1978-03-29 1979-03-08 Hydrocortisone 17-butyrate 21-propionate Expired GB2020291B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP53036251A JPS6040439B2 (en) 1978-03-29 1978-03-29 hydrocortisone derivatives

Publications (2)

Publication Number Publication Date
GB2020291A true GB2020291A (en) 1979-11-14
GB2020291B GB2020291B (en) 1982-10-06

Family

ID=12464544

Family Applications (1)

Application Number Title Priority Date Filing Date
GB7908189A Expired GB2020291B (en) 1978-03-29 1979-03-08 Hydrocortisone 17-butyrate 21-propionate

Country Status (11)

Country Link
US (1) US4290962A (en)
JP (1) JPS6040439B2 (en)
AR (1) AR221717A1 (en)
CH (1) CH638227A5 (en)
DE (1) DE2910899C2 (en)
FR (1) FR2421180A1 (en)
GB (1) GB2020291B (en)
IT (1) IT1116531B (en)
KE (1) KE3481A (en)
MY (1) MY8500791A (en)
SG (1) SG55584G (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2135576A (en) * 1983-01-31 1984-09-05 Taisho Pharmaceutical Co Ltd Hydrocortisone butyrate propionate creams
GB2135577A (en) * 1983-01-27 1984-09-05 Taisho Pharmaceutical Co Ltd Hydrocortisone butyrate propionate ointments

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2826257C3 (en) * 1978-06-15 1980-12-04 Beiersdorf Ag, 2000 Hamburg Hydrocortisone-17,21-diester and process for their preparation, pharmaceuticals containing them and hydrocortisone -17-propionate as an intermediate
ATE12237T1 (en) * 1980-12-23 1985-04-15 Schering Ag NEW 6-ALPHA-METHYLHYDROCORTISONE DERIVATIVES, THEIR PREPARATION AND USE.
DE3133081A1 (en) * 1981-08-18 1983-03-10 Schering Ag, 1000 Berlin Und 4619 Bergkamen NEW 6 (ALPHA) METHYLPREDNISOLONE DERIVATIVES, THEIR PRODUCTION AND USE
AT389447B (en) * 1983-01-27 1989-12-11 Taisho Pharmaceutical Co Ltd Process for the production of a topical steroid ointment
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
WO2006071794A2 (en) 2004-12-23 2006-07-06 Ethicon Incorporated Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
EP1641913B1 (en) 2003-06-27 2016-01-06 DePuy Synthes Products, Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
AU2004268847A1 (en) * 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
JP2009512676A (en) 2005-10-19 2009-03-26 ランバクシー ラボラトリーズ リミテッド Pharmaceutical composition of muscarinic receptor antagonist
EP1948167A1 (en) * 2005-10-19 2008-07-30 Ranbaxy Laboratories, Ltd. Compositions of phosphodiesterase type iv inhibitors
WO2007070870A1 (en) 2005-12-16 2007-06-21 Ethicon, Inc. Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
AU2007298549A1 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
ES2524443T3 (en) 2006-11-13 2014-12-09 DePuy Synthes Products, LLC In vitro expansion of postpartum cells using microcarriers
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
AU2008224541B2 (en) * 2007-03-14 2013-08-22 Sun Pharmaceutical Industries Limited Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
WO2008111009A1 (en) * 2007-03-14 2008-09-18 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
CN102387807A (en) * 2008-12-19 2012-03-21 先进科技及再生医学有限责任公司 Treatment of lung and pulmonary diseases and disorders
CN104356188A (en) * 2014-10-23 2015-02-18 华中药业股份有限公司 Preparation method of hydrocortisone butyrate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH429716A (en) * 1961-06-24 1967-02-15 Vismara Francesco Spa Process for the preparation of 17a-acyloxy-21-hydroxy steroids
GB1043347A (en) * 1963-05-10 1966-09-21 Glaxo Lab Ltd 17,21-orthoesters of steroids
GB1047518A (en) * 1963-06-11 1966-11-02 Glaxo Lab Ltd 17ª‡-monoesters of 11,17,21-trihydroxy steroid compounds
US3422193A (en) * 1966-08-11 1969-01-14 Schering Corp 17-mono esters of corticoids
DE2144405A1 (en) * 1971-09-04 1973-03-08 Merck Patent Gmbh Saponification of pregnane series esters - using silica gel
DE2826257C3 (en) * 1978-06-15 1980-12-04 Beiersdorf Ag, 2000 Hamburg Hydrocortisone-17,21-diester and process for their preparation, pharmaceuticals containing them and hydrocortisone -17-propionate as an intermediate

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2135577A (en) * 1983-01-27 1984-09-05 Taisho Pharmaceutical Co Ltd Hydrocortisone butyrate propionate ointments
GB2135576A (en) * 1983-01-31 1984-09-05 Taisho Pharmaceutical Co Ltd Hydrocortisone butyrate propionate creams

Also Published As

Publication number Publication date
FR2421180A1 (en) 1979-10-26
JPS54128560A (en) 1979-10-05
DE2910899A1 (en) 1979-10-11
SG55584G (en) 1985-03-08
US4290962A (en) 1981-09-22
CH638227A5 (en) 1983-09-15
FR2421180B1 (en) 1982-10-22
JPS6040439B2 (en) 1985-09-11
AR221717A1 (en) 1981-03-13
IT1116531B (en) 1986-02-10
DE2910899C2 (en) 1986-02-13
KE3481A (en) 1985-01-04
MY8500791A (en) 1985-12-31
IT7948501A0 (en) 1979-03-27
GB2020291B (en) 1982-10-06

Similar Documents

Publication Publication Date Title
GB2020291B (en) Hydrocortisone 17-butyrate 21-propionate
AU551471B2 (en) 9lamda-chloro-11beba-hydroxy-16beta-methyl-17lamda,21- dipropionyl-oxypregna-1,4-diene-3,20-dione
AU535148B2 (en) Branch-off method
AU2416477A (en) Motorized terrestrial surboard
AU501715B2 (en) Reinforcement joint
AU513579B2 (en) 11b-amino-alkanoyloxy or aralkanoyloxy pregnenes and androstanes
AU4844779A (en) System for following the sun
AU542273B2 (en) 10-alkynyl steroids
AU4560379A (en) Branch-off method
AU4558479A (en) Corticosteroid antiinflammatory agents
AU512101B2 (en) 19-oxygenated steroids
AU529413B2 (en) Steroids
AU540812B2 (en) Steroid alkaloids
AU5030679A (en) Leveling device for vehicles
AU529292B2 (en) 17-substituted pregnane steroids
AU527582B2 (en) 13-alkyl-18,19-dinor pregn-4-en-3,20-dione derivatives
AU534679B2 (en) Steroid immunogens
AU528292B2 (en) Halogenated 16alpha-methyl pregnane
AU523541B2 (en) Wind-propelled vehicle
SU694605A1 (en) Buried part
AU526405B2 (en) Photogrammetric apparatus
GB2022092B (en) Cephalosporin anaglogoues and processes for the preparation thereof
AU533384B2 (en) Corticoid 21 sulphorpropionates
AU544517B2 (en) Androstane carbothioates
JPS5538485A (en) Defroster

Legal Events

Date Code Title Description
732 Registration of transactions, instruments or events in the register (sect. 32/1977)
PE20 Patent expired after termination of 20 years

Effective date: 19990307